Showing 1,561 - 1,580 results of 120,134 for search '(( 2 n decrease ) OR ( 5 ((((mean decrease) OR (point decrease))) OR (a decrease)) ))', query time: 2.18s Refine Results
  1. 1561
  2. 1562

    Unusual [3+1] Cycloaddition of a Stable Silylene with a 2,3-Diazabuta-1,3-diene versus [4+1] Cycloaddition toward a Buta-1,3-diene by Yun Xiong (1403545)

    Published 2010
    “…Cycloaddition reactions of the thermally stable N-heterocyclic silylene LSi: <b>1</b> {L = CH[(CCH<sub>2</sub>)CMe][N(Ar)]<sub>2</sub>], Ar = 2,6-<i>i</i>Pr<sub>2</sub>C<sub>6</sub>H<sub>3</sub>} with acetone azine (1,1,4,4-tetramethyl-2,3-diazabuta-1,3-diene) and buta-1,3-diene derivatives have been probed. …”
  3. 1563
  4. 1564
  5. 1565
  6. 1566
  7. 1567
  8. 1568
  9. 1569
  10. 1570

    Cytotoxic effect of Eltrombopag on AML cells is dependent on dose and serum concentration. by Anna Kalota (7415)

    Published 2015
    “…Graphs demonstrate decrease in a total cell number after exposure to 5 μM E at 2% serum, presented as a percent of control at day 2 for cell lines and day 4 for primary cells.…”
  11. 1571
  12. 1572
  13. 1573

    Decreased clonal burden in relapses over time. by Rintis Noviyanti (106250)

    Published 2022
    “…Similarly, relapses in 18 Cambodian soldiers determined genotypically to have relapse <a href="https://paperpile.com/c/lfW4ac/V4Y4V" target="_blank">[13</a>] suggest a decrease in MOI from their initial vivax episode to relapse (slope = -0.03, p = 0.20). …”
  14. 1574
  15. 1575
  16. 1576
  17. 1577

    Table_5_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  18. 1578
  19. 1579
  20. 1580